Cresset Asset Management LLC Decreases Stock Position in Genmab A/S Sponsored ADR $GMAB

Key Points

• Cresset Asset Management LLC reduced its stake in Genmab A/S by 51.6%, now holding 12,468 shares worth $244,000.
• Several hedge funds have increased their positions in Genmab A/S, with American Century Companies Inc. growing theirs by 19.8% in the first quarter.
• Genmab A/S reported $0.54 earnings per share for the last quarter, exceeding estimates, and has a current price target consensus of $37.60 from analysts.

Cresset Asset Management LLC decreased its position in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 51.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 12,468 shares of the company's stock after selling 13,284 shares during the quarter. Cresset Asset Management LLC's holdings in Genmab A/S were worth $244,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the company. Deep Track Capital LP acquired a new position in Genmab A/S in the 4th quarter valued at about $41,740,000. Brandywine Global Investment Management LLC grew its holdings in Genmab A/S by 6.0% in the 1st quarter. Brandywine Global Investment Management LLC now owns 1,717,397 shares of the company's stock valued at $33,627,000 after buying an additional 97,633 shares during the period. Two Sigma Investments LP grew its holdings in Genmab A/S by 122.2% in the 4th quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company's stock valued at $35,612,000 after buying an additional 938,455 shares during the period. Two Sigma Advisers LP grew its holdings in Genmab A/S by 168.8% in the 4th quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company's stock valued at $34,509,000 after buying an additional 1,038,400 shares during the period. Finally, Voloridge Investment Management LLC grew its holdings in Genmab A/S by 102.4% in the 4th quarter. Voloridge Investment Management LLC now owns 1,110,191 shares of the company's stock valued at $23,170,000 after buying an additional 561,767 shares during the period. Institutional investors and hedge funds own 7.07% of the company's stock.

Analyst Ratings Changes

Several analysts have commented on GMAB shares. Wall Street Zen upgraded Genmab A/S from a "hold" rating to a "buy" rating in a report on Monday, July 28th. HC Wainwright lifted their price target on Genmab A/S from $35.00 to $36.00 and gave the company a "buy" rating in a report on Friday, August 15th. Zacks Research cut Genmab A/S from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Finally, Truist Financial lifted their price target on Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a report on Tuesday, July 8th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Genmab A/S presently has a consensus rating of "Moderate Buy" and a consensus target price of $37.60.

Genmab A/S Stock Down 1.0%

Shares of NASDAQ GMAB traded down $0.24 during midday trading on Monday, hitting $24.87. The stock had a trading volume of 676,680 shares, compared to its average volume of 1,316,170. The company has a market capitalization of $15.96 billion, a price-to-earnings ratio of 12.50, a PEG ratio of 7.22 and a beta of 0.93. Genmab A/S Sponsored ADR has a 1-year low of $17.24 and a 1-year high of $27.93. The company has a fifty day moving average price of $22.22 and a 200 day moving average price of $21.28.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.15. The business had revenue of $925.00 million for the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS. On average, research analysts forecast that Genmab A/S Sponsored ADR will post 1.45 EPS for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.